CD40 expression is highly sensitive and specific for differentiating between classic Hodgkin lymphoma and ALK-negative anaplastic large cell lymphoma
In brief
CD40 staining detects 98.6% of classic Hodgkin lymphoma, with no ALCL positives
CD40 immunohistochemistry identified 98.6% of classic Hodgkin lymphoma cases and was negative in every ALK-negative anaplastic large cell lymphoma case, including diagnostically ambiguous cases. It could strengthen diagnostic panels when usual lineage markers are absent, but background staining and the need for studies in broader lymphoma populations remain important limitations.
- Journal
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Q1)
- Published
- 18 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Theresa Spivey, Achim Jungbluth, Rene Serrette, Ting Zhou, Ozgur Can Eren, Jeeyeon Baik, et al.
- PMID
- 43051594
- DOI
- 10.1016/j.modpat.2026.101119
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (top studies of the week, 22 November 2026): Evaluates CD40 IHC for a challenging lymphoma differential
Abstract
Distinguishing classic Hodgkin lymphoma (CHL) from anaplastic large cell lymphoma (ALCL) can be diagnostically challenging, particularly in cases where lineage-defining markers are diminished or absent. Both entities are CD30-positive lymphomas and may share overlapping morphologic features, including atypical cytology and disrupted immunophenotypic expression. While B-cell markers such as PAX5, OCT2, and BOB1 are used to support B-cell lineage in CHL, their inconsistent expression can limit diagnostic confidence. In this study, we evaluated the performance of CD40 immunohistochemistry (IHC) in a cohort of CD30-positive lymphomas. CD40, a receptor involved in B-cell activation and differentiation, has been previously reported in Hodgkin/Reed-Sternberg cells, but its diagnostic utility in this setting has not been comprehensively assessed in clinical practice or in this differential. Our findings show that CD40 IHC demonstrates 98.6% sensitivity and 100% specificity for CHL, including in diagnostically ambiguous cases such as PAX5-negative CHL and ALK-negative ALCL with a null phenotype. Notably, CD40 was consistently negative in all ALCL cases, including those requiring a clinicopathologic consensus diagnosis, underscoring its potential as a reliable marker of B-cell lineage. Although background staining in histiocytes and dendritic cells may complicate interpretation, careful morphologic correlation helps mitigate this issue. These results support the inclusion of CD40 into diagnostic panels for CD30-positive lymphomas with unclear lineage differentiation. Further comparative studies may help define its role alongside other B-cell markers and expand its utility across a broader range of lymphoid neoplasms.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.